Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.mehy.2021.110534 http://scihub22266oqcxt.onion/10.1016/j.mehy.2021.110534 33640714!7881296!33640714     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+Hypotheses 2021 ; 149 (ä): 110534 Nephropedia Template TP {{tp|p=33640714|t=2021. Can bilirubin nanomedicine become a hope for the management of COVID-19?|pdf=|usr=}}{{33640714}} gab.com Text Can bilirubin nanomedicine become a hope for the management of COVID-19 JO: Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=33640714 #FOAvip Bilirubin has been proven to possess significant anti-inflammatory, antioxidant and antiviral activities. Recently, it has been postulated as a metabolic hormone. Further, moderately higher levels of bilirubin are positively associated with reduced risk of cardiovascular diseases, diabetes, metabolic syndrome and obesity. However, due to poor solubility the therapeutic delivery of bilirubin remains a challenge. Nanotechnology offers unique advantages which may be exploited for improved delivery of bilirubin to the target organ with reduced risk of systemic toxicity. Herein, we postulate the use of intravenous administration or inhalational delivery of bilirubin nanomedicine (BNM) to combat systemic dysfunctions associated with COVID-19, owing to the remarkable preclinical efficacy and optimistic results of various clinical studies of bilirubin in non-communicable disorders. BNM may be used to harness the proven preclinical pharmacological efficacy of bilirubin against COVID-19 related systemic complications. Twit Text FOAVip Can bilirubin nanomedicine become a hope for the management of COVID-19 ????Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=33640714 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33640714 #FOAvip English Wikipedia <ref>{{Cite pmid|33640714}}</ref> Can bilirubin nanomedicine become a hope for the management of COVID-19? #MMPMID33640714 Khurana I; Allawadhi P; Khurana A; Srivastava AK; Navik U; Banothu AK; Bharani KK Med Hypotheses 2021[Apr]; 149 (ä): 110534 PMID33640714show ga Bilirubin has been proven to possess significant anti-inflammatory, antioxidant and antiviral activities. Recently, it has been postulated as a metabolic hormone. Further, moderately higher levels of bilirubin are positively associated with reduced risk of cardiovascular diseases, diabetes, metabolic syndrome and obesity. However, due to poor solubility the therapeutic delivery of bilirubin remains a challenge. Nanotechnology offers unique advantages which may be exploited for improved delivery of bilirubin to the target organ with reduced risk of systemic toxicity. Herein, we postulate the use of intravenous administration or inhalational delivery of bilirubin nanomedicine (BNM) to combat systemic dysfunctions associated with COVID-19, owing to the remarkable preclinical efficacy and optimistic results of various clinical studies of bilirubin in non-communicable disorders. BNM may be used to harness the proven preclinical pharmacological efficacy of bilirubin against COVID-19 related systemic complications. |Anti-Inflammatory Agents/therapeutic use[MESH] |Antioxidants/therapeutic use[MESH] |Antiviral Agents/therapeutic use[MESH] |Bilirubin/*therapeutic use[MESH] |Biliverdine/therapeutic use[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/*therapy[MESH] |Cytokine Release Syndrome[MESH] |Humans[MESH] |Inflammation[MESH] |MAP Kinase Signaling System[MESH] |Models, Theoretical[MESH] |NF-kappa B p50 Subunit/metabolism[MESH] |Nanomedicine/*methods[MESH] |Risk[MESH] |Signal Transduction[MESH]Can bilirubin nanomedicine become a hope for the management of COVID-1(epmc).pdf DeepDyve Pubget Overpricing